US-based online healthcare platform Lemonaid Health has raised $11m in a series A round co-led by the corporate venturing units of pharmaceutical companies Novartis and Hikma Pharmaceuticals.
Novartis Venture Fund and Hikma Ventures were joined by venture capital firms Correlation Ventures and 415 Ventures, investment fund Adaptive Healthcare Fund, and VC firm and consulting boutique Vega Ventures.
Lemonaid has built an online platform that facilitates prescriptions for birth control pills and conditions such as acid reflux, influenza, hair loss and urinary tract infections in return for a $15 administrative fee.
A number of certified doctors work with the service, recommending treatment where required and submitting prescriptions to the user’s selected pharmacy. The service was launched in 2015 and is currently available in 14 US states.
Paul Johnson, co-CEO of Lemonaid Health, said: “This new capital will accelerate our development of future product capabilities while expanding Lemonaid’s operating footprint.
“We are using technology to augment physicians’ ability to provide standardised and streamlined quality care at scale. “We are thrilled that our partners can see how machine learning and other technologies will increase access to timely care and improve affordability.”
Formerly known as Icebreaker Health, Lemonaid raised $6.6m in a 2015 seed round and a further $1.7m in July 2016, according to regulatory filings.